Given the potential interaction between loss of PTEN expression and VEGF pathway activation and importantly the uncertainty in relation to its impact on prognosis, we undertook an analysis of tumor samples collected during the course of the AGITG MAX trial, which involved patients with advanced colorectal cancer receiving chemotherapy with or without the anti-VEGF antibody bevacizumab. This evidence concerns the gene PTEN and neoplasm.